MedTrace Logo

Spyglass+RFA Versus Cytobrush+RFA for Extrahepatic Cholangiocarcinoma

NCT05233293 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2023-08-15

No results posted yet for this study

Summary

With the development of endoscopic technology, endoscopic retrograde cholangiopancreatography (ERCP) has been widely used in the diagnosis and treatment of extrahepatic cholangiocarcinoma.In patients with extrahepatic cholangiocarcinoma, cytological brushing performed concurrently with ERCP had a lower pathologically positive rate and increased the times of ERCPs, increased the risk of postoperative complications at the same time.The present study aims to compare the efficacy and safety outcomes of Spyglass+RFA Versus Cytobrush+RFA for Extrahepatic Cholangiocarcinoma.

Conditions

  • Extrahepatic Cholangiocarcinoma
  • Malignant Biliary Obstruction

Interventions

PROCEDURE

Spyglass + RFA

SpyGlass direct Vision guided RFA

PROCEDURE

Cytobrush + RFA

After Cytobrush ,taking RFA through ERCP

Sponsors & Collaborators

  • First People's Hospital of Hangzhou

    lead OTHER

Principal Investigators

  • Jianfeng Yang · First People's Hospital of Hangzhou

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-01
Primary Completion
2023-10-01
Completion
2023-10-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05233293 on ClinicalTrials.gov